Surgery Partnersの空売り状況は、投資家がSurgery Partnersの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Surgery Partners (NASDAQ:SGRY) 株価情報, 空売り情報

Surgery Partners

Surgery Partners Inc is a healthcare services company with an integrated outpatient delivery model focused on providing quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. It operates in two segments: Surgical Facility Services and Ancillary Services out of which the Surgical Facility Services segment accounts for the majority of revenue.

Surgery Partners Inc

UBS analyst Jay Sole maintains VF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VFC#NYSE">VFC</a>) with a Neutral and raises the price target from $24 to $28.

News

Price Target

Analyst Ratings

UBS Maintains Neutral on VF, Raises Price Target to $28

UBS analyst Lloyd Walmsley maintains Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) with a Buy and raises the price target from $736 to $786.

UBS Maintains Buy on Meta Platforms, Raises Price Target to $786

UBS analyst Joseph Spak maintains Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) with a Sell and raises the price target from $226 to $259.

TSLA

UBS Maintains Sell on Tesla, Raises Price Target to $259

UBS analyst Ashwani Verma maintains Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Buy and raises the price target from $162 to $176.

NBIX

UBS Maintains Buy on Neurocrine Biosciences, Raises Price Target to $176

AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) has outperformed the market over the past 5 years by 2.84% on an annualized basis producing an average annual return of 15.8%. Currently, AbbVie has a market capitalization of $310.89 billion. 
Buying $100 In ABBV: If an investor had bought $100 of ABBV stock 5 years ago, it would be worth $213.43 today based on a price of $175.93 for ABBV at the time of writing.
<h3>AbbVie's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738278910_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

ABBV

$100 Invested In AbbVie 5 Years Ago Would Be Worth This Much Today

TD Securities analyst Craig Hutchison maintains MAG Silver (TSX:<a class="ticker" href="https://www.benzinga.com/stock/MAG#TSX">MAG</a>) with a Buy and raises the price target from C$26 to C$27.

TSX:MAG

TD Securities Maintains Buy on MAG Silver, Raises Price Target to C$27

TD Securities analyst Daniel Chan maintains CGI (TSX:<a class="ticker" href="https://www.benzinga.com/stock/GIB#TSX">GIB</a>) with a Buy and raises the price target from C$180 to C$190.

TSX:GIB

TSX:GIB/A

TD Securities Maintains Buy on CGI, Raises Price Target to C$190

Citigroup analyst Ronald Josey maintains Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) with a Buy and raises the price target from $753 to $780.

Citigroup Maintains Buy on Meta Platforms, Raises Price Target to $780

Citigroup analyst Jon Tower maintains Brinker International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAT#NYSE">EAT</a>) with a Neutral and raises the price target from $166 to $185.

Citigroup Maintains Neutral on Brinker International, Raises Price Target to $185

Citigroup analyst Scott Gruber maintains Seadrill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SDRL#NYSE">SDRL</a>) with a Buy and lowers the price target from $50 to $46.

SDRL

Citigroup Maintains Buy on Seadrill, Lowers Price Target to $46

American Express (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) has outperformed the market over the past 5 years by 6.37% on an annualized basis producing an average annual return of 19.32%. Currently, American Express has a market capitalization of $223.90 billion. 
Buying $100 In AXP: If an investor had bought $100 of AXP stock 5 years ago, it would be worth $243.47 today based on a price of $318.95 for AXP at the time of writing.
<h3>American Express's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738278015_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning American Express Stock In The Last 5 Years

Citigroup analyst Scott Gruber maintains Valaris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VAL#NYSE">VAL</a>) with a Neutral and raises the price target from $47 to $48.

Citigroup Maintains Neutral on Valaris, Raises Price Target to $48

Citigroup analyst Asiya Merchant maintains Western Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) with a Buy and lowers the price target from $82 to $80.

Citigroup Maintains Buy on Western Digital, Lowers Price Target to $80

Citigroup analyst Patrick Donnelly maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Buy and lowers the price target from $285 to $265.

Citigroup Maintains Buy on Danaher, Lowers Price Target to $265

Citigroup analyst George Choi maintains Las Vegas Sands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LVS#NYSE">LVS</a>) with a Buy and raises the price target from $64.5 to $67.

Citigroup Maintains Buy on Las Vegas Sands, Raises Price Target to $67

Maxim Group analyst Jason McCarthy maintains Alterity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHE#NASDAQ">ATHE</a>) with a Buy and raises the price target from $8 to $12.

Alterity Therapeutics Limited - American Depositary Shares

ATHE

Maxim Group Maintains Buy on Alterity Therapeutics, Raises Price Target to $12

Earnings

HFBL

CORRECTION: Home Federal Bancorp Q2 EPS $0.33, Flat YoY

Cheniere Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNG#NYSE">LNG</a>) has outperformed the market over the past 5 years by 18.24% on an annualized basis producing an average annual return of 31.2%. Currently, Cheniere Energy has a market capitalization of $51.65 billion. 
Buying $1000 In LNG: If an investor had bought $1000 of LNG stock 5 years ago, it would be worth $3,918.96 today based on a price of $230.20 for LNG at the time of writing.
<h3>Cheniere Energy's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738277138_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Cheniere Energy 5 Years Ago Would Be Worth This Much Today

Shares of Common Stock are expected to begin trading on the New York Stock Exchange under the ticker symbol "INR." The offering is expected to close on February 3, 2025, subject to customary closing conditions.

IPOs

Infinity Natural Resources Prices Public Offering Of 13.25M Shares Of Class A Common Stock At $20.00 Per Share

Maxim Group analyst Allen Klee initiates coverage on Orangekloud Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORKT#NASDAQ">ORKT</a>) with a Buy rating and announces Price Target of $5.

Initiation

ORKT

Maxim Group Initiates Coverage On Orangekloud Technology with Buy Rating, Announces Price Target of $5

HCA Healthcare posts Q4 earnings miss amid hurricane impact

Surgery Partners jumps on $25.75 a share offer from Bain Capital Private Equity

Surgery Partners' takeover offer should rekindle interest - analyst

Surgery Partners jumps on $25.75 a share offer from Bain Capital (update)

Surgery Partners (SGRY) announced that its board received a non-binding proposal, dated January 27, from Bain Capital Private Equity to acquire all...

Surgery Partners says committee to review $25.75 per share buyout proposal

13:04 EST Surgery Partners (SGRY) confirms $25.75 per share buyout offer from Bain Capital Published first on TheFly – the ultimate source for real...

Surgery Partners confirms $25.75 per share buyout offer from Bain Capital

Mizuho Securities analyst Ann Hynes maintained a Buy rating on Surgery Partners (SGRY – Research Report) yesterday. The company's shares closed yes...

Mizuho Securities Sticks to Their Buy Rating for Surgery Partners (SGRY)

BofA analyst Joanna Gajuk is moving to No Rating on Surgery Partners (SGRY) after Bain Capital made a non-binding proposal to buy the 61% stake it ...

BofA moves to No Rating on Surgery Partners after Bain offer

Analyst Whit Mayo of Leerink Partners reiterated a Buy rating on Surgery Partners (SGRY – Research Report), with a price target of $36.00. Whit May...

Comments

Surgery Partners

空売り

Surgery Partners (NASDAQ:SGRY) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル